PubRank

Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer (LUTRAERL)

Clinical Trial ID NCT00473083

PubWeight™ 3.15‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00473083

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 31.48
2 Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995 9.03
3 Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005 2.43
4 HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005 2.17
5 Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997 2.03
6 Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987 1.83
7 Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol 2015 1.65
8 Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer 1986 1.45
9 Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001 1.44
10 The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993 1.37
11 Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995 1.27
12 A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996 1.13
13 Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003 1.05
14 Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996 0.97
15 The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). Int J Oncol 1994 0.93
16 Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002 0.91
17 Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999 0.87
18 The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996 0.85
19 Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 1999 0.84
20 Management of egfr tki-induced dermatologic adverse events. Curr Oncol 2015 0.82
21 Unilateral onycholysis in a patient taking erlotinib (Tarceva). BMJ Case Rep 2011 0.78
22 Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. Oncol Rep 1998 0.76
23 Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 1996 0.75
Next 100